Published in Neurobehav HIV Med on August 01, 2010
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 6.91
Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med (1986) 4.26
National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry (2006) 3.38
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 3.35
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. J Child Psychol Psychiatry (2009) 2.57
Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection. Pediatrics (2009) 1.79
FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse. JAMA (2009) 1.46
Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment. Pediatrics (2006) 1.42
Screening for lipid disorders in children: US Preventive Services Task Force recommendation statement. Pediatrics (2007) 1.41
Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry (2005) 1.39
Mental health treatment patterns in perinatally HIV-infected youth and controls. Pediatrics (2009) 1.34
Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet (2005) 1.32
Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J (2005) 1.23
Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection. Pediatrics (2005) 1.13
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry (2008) 1.10
Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J Acquir Immune Defic Syndr (2008) 1.09
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS (2010) 1.07
Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry (2008) 1.07
Review of antipsychotics in children and adolescents. Expert Opin Pharmacother (2006) 0.89
Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study. Pharmacoepidemiol Drug Saf (2009) 0.84
Impact of medications prescribed for treatment of attention-deficit hyperactivity disorder on physical growth in children and adolescents with HIV. J Dev Behav Pediatr (2009) 0.82
The use of second-generation antipsychotics and the changes in physical growth in children and adolescents with perinatally acquired HIV. AIDS Patient Care STDS (2009) 0.80
Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ (2013) 3.88
Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2009) 3.52
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis (2008) 3.09
Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr (2010) 2.96
Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA (2006) 2.96
Characterization of phthalate exposure among pregnant women assessed by repeat air and urine samples. Environ Health Perspect (2008) 2.75
Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics (2006) 2.62
Variability of urinary phthalate metabolite and bisphenol A concentrations before and during pregnancy. Environ Health Perspect (2012) 2.43
Polymorphisms in the mannose binding lectin-2 gene and acute respiratory distress syndrome. Crit Care Med (2007) 2.31
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS (2012) 2.19
Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2004) 2.17
Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS (2009) 2.16
An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf (2005) 2.15
Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet (2003) 2.04
Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis (2003) 2.04
Predictors and variability of urinary paraben concentrations in men and women, including before and during pregnancy. Environ Health Perspect (2012) 1.96
Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA (2005) 1.91
Barriers to medication adherence in HIV-infected children and youth based on self- and caregiver report. Pediatrics (2012) 1.85
Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Clin Infect Dis (2011) 1.83
Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection. Pediatrics (2009) 1.79
Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One (2010) 1.77
Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations. PLoS One (2013) 1.74
The association of particulate air metal concentrations with heart rate variability. Environ Health Perspect (2002) 1.71
Serum concentrations of polychlorinated biphenyls in relation to in vitro fertilization outcomes. Environ Health Perspect (2011) 1.60
Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. J Acquir Immune Defic Syndr (2003) 1.60
Gender differences in health-related quality of life in patients with HIV/AIDS. Qual Life Res (2005) 1.60
Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis (2008) 1.60
NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine. Birth Defects Res B Dev Reprod Toxicol (2004) 1.57
Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis (2004) 1.54
Plasma C-reactive protein in early pregnancy and preterm delivery. Am J Epidemiol (2005) 1.53
Sexual behaviors and procreational intentions of adolescents and young adults with perinatally acquired human immunodeficiency virus infection: experience of an urban tertiary center. J Adolesc Health (2006) 1.52
Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection. Pediatrics (2004) 1.51
Mental health functioning among children and adolescents with perinatal HIV infection and perinatal HIV exposure. AIDS Care (2011) 1.51
Urinary bisphenol A concentrations and early reproductive health outcomes among women undergoing IVF. Hum Reprod (2012) 1.48
Maternal urinary metabolites of Di-(2-Ethylhexyl) phthalate in relation to the timing of labor in a US multicenter pregnancy cohort study. Am J Epidemiol (2009) 1.47
Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. Arch Pediatr Adolesc Med (2004) 1.44
Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment. Pediatrics (2006) 1.42
Toxicities of antiretroviral therapy in children. AIDS Read (2006) 1.42
Challenges in using observational studies to evaluate adverse effects of treatment. N Engl J Med (2007) 1.42
Impact of HIV severity on cognitive and adaptive functioning during childhood and adolescence. Pediatr Infect Dis J (2012) 1.41
Genetic modification of the association between peripubertal dioxin exposure and pubertal onset in a cohort of Russian boys. Environ Health Perspect (2012) 1.39
Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics (2007) 1.38
The association between personal measurements of environmental exposure to particulates and heart rate variability. Epidemiology (2002) 1.38
Co-occuring psychiatric symptoms in children perinatally infected with HIV and peer comparison sample. J Dev Behav Pediatr (2010) 1.36
Urinary bisphenol A concentrations and implantation failure among women undergoing in vitro fertilization. Environ Health Perspect (2012) 1.34
Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis (2004) 1.33
Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J (2010) 1.31
The role of cognitive functioning in medication adherence of children and adolescents with HIV infection. J Pediatr Psychol (2008) 1.30
A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol (2003) 1.29
Who will speak for me? Improving end-of-life decision-making for adolescents with HIV and their families. Pediatrics (2009) 1.28
Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr (2006) 1.27
In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS (2011) 1.26
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol (2010) 1.26
HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS (2007) 1.25
Combination antiretroviral use and preterm birth. J Infect Dis (2012) 1.25
Allocation of family responsibility for illness management in pediatric HIV. J Pediatr Psychol (2008) 1.24
Arsenic exposure and cancer mortality in a US-based prospective cohort: the strong heart study. Cancer Epidemiol Biomarkers Prev (2013) 1.23
Longitudinal study of emerging mental health concerns in youth perinatally infected with HIV and peer comparisons. J Dev Behav Pediatr (2012) 1.20
Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study. J Acquir Immune Defic Syndr (2011) 1.19
Folic acid-containing supplement consumption during pregnancy and risk for oral clefts: a meta-analysis. Birth Defects Res A Clin Mol Teratol (2007) 1.19
Assessment of adherence to antiretroviral therapy in perinatally HIV-infected children and youth using self-report measures and pill count. J Dev Behav Pediatr (2008) 1.18
When should we treat children with HIV? J Pediatr (Rio J) (2006) 1.16
Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med (2009) 1.16
Maternal periodontitis and adverse pregnancy outcomes. Community Dent Oral Epidemiol (2008) 1.15
Medication adherence in children and adolescents with HIV infection: associations with behavioral impairment. AIDS Patient Care STDS (2011) 1.14
Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care (2011) 1.13
Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection. Pediatrics (2005) 1.13
Measuring anxiety as a treatment endpoint in youth with autism spectrum disorder. J Autism Dev Disord (2014) 1.12
Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr (2009) 1.11
Predictors of serum dioxins and PCBs among peripubertal Russian boys. Environ Health Perspect (2009) 1.11
Improving the reliability of autism diagnoses: examining the utility of adaptive behavior. J Autism Dev Disord (2007) 1.11
Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis (2008) 1.10
Short communication: transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected children. AIDS Res Hum Retroviruses (2011) 1.09
Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J Acquir Immune Defic Syndr (2008) 1.09
Do-not-resuscitate orders and/or hospice care, psychological health, and quality of life among children/adolescents with acquired immune deficiency syndrome. J Palliat Med (2008) 1.09
Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead. AIDS Res Hum Retroviruses (2010) 1.08
Language impairment in children perinatally infected with HIV compared to children who were HIV-exposed and uninfected. J Dev Behav Pediatr (2012) 1.08